Azelastine-13C,d3 (hydrochloride)

• UNSPSC Description:

  Azelastine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled Azelastine hydrochloride. Azelastine-13C,d3 (hydrochloride), an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine-13C,d3 (hydrochloride) can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2[1][2][3][4].

• Target Antigen:

  Histamine Receptor; Isotope-Labeled Compounds; SARS-CoV

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling;Others

• Field of Research:

  Infection; Endocrinology; Metabolic Disease; Inflammation/Immunology

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C2=CC=CC=C2C(CC3=CC=C(C=C3)Cl)=NN1C4CCCN(CC4)[13C]([2H])([2H])[2H].[H]Cl

• Molecular Weight:

  422.37

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Craig La Force. Review of the pharmacology, clinical efficacy, and safety of azelastine hydrochloridel. Expert Rev Clin Immunol. 2005 Jul;1(2):191-201.|[3]Mohamed M Elseweidy, et al. Azelastine a potent antihistamine agent, as hypolipidemic and modulator for aortic calcification in diabetic hyperlipidemic rats model. Arch Physiol Biochem. 2020 Jul 2;1-8.|[4]Carlos D. Zappia, et al. Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model. Pharmacol Res Perspect. 2019 Dec; 7(6): e00531.|[5]Li Yang, et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol Sin. 2020 Oct 28 : 1–7.|[6]Shao-Cheng Liu, et al. Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells. Eur Arch Otorhinolaryngol. 2017 Feb;274(2):845-853.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported